LoQus23: going upstream to slow Huntington’s disease
By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean it up afterwards
Rather than targeting mutant HTT to treat Huntington’s disease, LoQus23 is instead developing a small molecule that acts upstream to stop the aberrant DNA damage repair pathway responsible for creating the gene’s mutations.
LoQus23 Therapeutics Ltd. emerged from stealth mode in November with funding from the Novartis Venture and Dementia Discovery funds. The Dementia Discovery Fund invested an initial £4.5 million ($5.9 million) seed investment in 2019 and, together with the Novartis Venture Fund, a further $9.4 million last fall. ...